Company Overview and News

Teranga Gold - I Am Optimistic In The Medium Term

2018-03-07 seekingalpha
In the medium term Teranga share prices should be supported by the company's largest shareholder; since November 2017 this shareholder has purchased 2.05 million shares and is still buying.
Upvote Downvote

Teranga Gold: Get By With A Little Help From Gold Prices

2018-03-05 seekingalpha
Teranga Gold has an achievable organic growth pipeline supported by strong free cash flows from current operations.
Upvote Downvote

Top 20 Gold Mining Stocks For 2018

2018-01-02 seekingalpha
Above are my Top 20 gold mining stocks for 2018. All of these companies have large resources and are highly undervalued based on their cash flow potential at higher gold prices. They are on this list primarily because of their upside potential. These are either producers or development stocks, although there is one optionality play (Goldmining Inc).
Upvote Downvote

Teranga Gold Cornerstone Investor To Buy More Shares

2017-11-21 seekingalpha
On 17 November 2017, West Africa-focused gold miner Teranga Gold ( OTCPK:TGCDF) announced that its cornerstone investor David Mimran intends to acquire up to 5% of the its shares over the next twelve months. This will not result in shareholder dilution. Also, the cap on his position in Teranga has been lifted from 19.9% to 29.9%. Mimran currently holds a 19.8% stake in Teranga.
Upvote Downvote

Teranga Is Aiming To Become A Mid-Tier Gold Producer But The Market Isn't Buying It

2017-11-20 seekingalpha
In two separate announcements last week, the company delivered great drill results at its 'Golden Hill' project in Burkina Faso.
Upvote Downvote

Teranga Gold Corp's (TGCDF) CEO Richard Young on Q3 2017 Results - Earnings Call Transcript

2017-11-04 seekingalpha
Teranga Gold Corp CDA (OTCPK:TGCDF) Q3 2017 Results Earnings Conference Call November 2, 2017 8:30 AM ET
Upvote Downvote

Admission to AIM and First Day of Dealings

2017-08-10 londonstockexchange
Upvote Downvote

Teranga Gold's (TGCDF) CEO Richard Young on Q2 2017 Results - Earnings Call Transcript

2017-07-29 seekingalpha
Teranga Gold Corp CDA (OTCPK:TGCDF) Q2 2017 Earnings Conference Call July 28, 2017 8:30 AM ET
Upvote Downvote

Is Teranga Gold Still A Solid Growth Stock?

2017-07-25 seekingalpha
Teranga Gold's stock has underperformed this year; my previous #10 gold stock pick is down nearly 30% YTD.
Upvote Downvote

Teranga Gold Achieves Record Q2 Production and Confirms Banfora Feasibility Study Results Expected in August

2017-07-13 marketwired
- Board approves an additional $10 million towards construction readiness activities at Banfora gold project in advance of major construction decision
Upvote Downvote

Sarama Resources Increases Exploration Interests in the Hounde Belt, Burkina Faso

2017-05-16 marketwired
VANCOUVER, BC--(Marketwired - May 16, 2017) - Sarama Resources Ltd. ("Sarama" or the "Company") (TSX VENTURE: SWA) is pleased to advise that it has agreed to acquire a 100% interest in the Botoro exploration property ("Botoro" or the "Property") in south-west Burkina Faso. Botoro complements Sarama's mineral property interests in the highly prospective southern Houndé Belt and increases the size of its 100%-owned4 ThreeBee Project to approximately 660km².
Upvote Downvote

Teranga Gold Announces Effective Date of 1 for 5 Share Consolidation

2017-05-03 marketwired
TORONTO, ONTARIO--(Marketwired - May 3, 2017) - Teranga Gold Corporation ("Teranga" or the "Company") (TSX:TGZ)(ASX:TGZ) is pleased to announce that the 1 for 5 consolidation of its common shares ("Common Shares") that was approved at the recent annual and special meeting of shareholders of the Company ("Shareholders"), will be effective on May 5, 2017. The Common Shares are expected to commence trading on the Toronto Stock Exchange on a post-consolidation basis on May 8, 2017.
Upvote Downvote

Teranga Gold Announces Voting Results From Annual and Special Meeting of Shareholders

2017-05-02 marketwired
TORONTO, ONTARIO--(Marketwired - May 2, 2017) - Teranga Gold Corporation ("Teranga" or the "Company") (TSX:TGZ)(ASX:TGZ) announced that all nominee directors listed in the Management Proxy Circular dated April 3, 2017 were elected as directors of the Company at its Annual and Special Meeting of Shareholders (the "Meeting") held earlier today in Toronto, Ontario. At this Meeting, 311,621,281 shares were voted, representing 58.
Upvote Downvote

Teranga Gold Annual and Special Meeting of Shareholders Scheduled for May 2, 2017

2017-04-28 marketwired
TORONTO, ONTARIO--(Marketwired - April 28, 2017) - Teranga Gold Corporation ("Teranga" or the "Company") (TSX:TGZ)(ASX:TGZ) announced today that it will host Teranga's Annual and Special Meeting of Shareholders on Tuesday, May 2, 2017 at 9:30 a.m. ET at the TMX Broadcast Centre in The Exchange Tower located at 130 King Street West, Toronto, Ontario.
Upvote Downvote

Teranga Gold Reports Strong Q1 2017 Production and Financial Results

2017-04-27 marketwired
Organic growth prospects advancing with the completion of the Banfora feasibility study on track for mid-year and two gold discoveries at Golden Hill
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: Q4352M109